Vir Biotechnology, Inc. is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to cure serious infectious diseases. The Company’s lead candidate, VIR-2218, is a subcutaneously administered, HBV-targeting siRNA currently being studied in a Phase I/II trial in collaboration with Alnylam Pharmaceuticals.